DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.

Author(s): Chow LW, Yip AY, Loo WT, Lam CK, Toi M

Affiliation(s): Department of Surgery, University of Hong Kong Medical Centre, Pokfulam, Hong Kong; Organisation for Oncology and Translational Research, Hong Kong; Comprehensive Centre for Breast Diseases, UNIMED Medical Institute, 10/F, Luk Kwok Centre, 72 Gloucester Road, Wanchai, Hong Kong.

Publication date & source: 2008-07, J Steroid Biochem Mol Biol., 111(1-2):13-17. Epub 2008 Apr 20.

OBJECTIVES: To evaluate the efficacy and safety of combing aromatase inhibitor (AI) and cyclooxygenase-2 (COX-2) inhibitor neoadjuvantly in postmenopausal patients with invasive hormone-sensitive breast cancer. METHODS: Eighty-two patients were randomly assigned to receive exemestane 25mg daily and celecoxib 400mg twice daily (group A, n=30), exemestane 25mg daily (group B, n=24) and letrozole 2.5mg daily (group C, n=28). RESULTS: All groups showed clinical responses (58.6% for group A, 54.5% for group B and 62.0% for group C) and decrease in tumor area (61.8% for group A, 58.1% for group B and 55.7% for group C). 3 out of 5 patients with complete clinical response were observed from group A and 2 out of 69 patients operated with pathologic complete response were observed in group C. The mean microscopic tumor size was 2.53cm for group A, 3.05cm for group B and 2.10cm for group C. The differences were only statistically significant when group C was compared with group B (P=0.025). The toxicity profiles among groups were satisfactory. CONCLUSION: AI is effective in treating breast cancer and may be safely used preoperatively. The addition of COX-2 inhibitor may provide additional benefit.

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017